CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure

Documenti analoghi

• Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies
  di: Larisa H. Cavallari, et al.
  Pubblicazione: (2024)
• CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI
  di: Diona Gjermeni, et al.
  Pubblicazione: (2026)
• Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles
  di: Matthew H. Bennett, et al.
  Pubblicazione: (2026)
• CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin
  di: Rubin Lubomirov, et al.
  Pubblicazione: (2025)
• Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients
  di: Daniel Brazeau, et al.
  Pubblicazione: (2025)